

Tengion raises \$74M for organ programs

Published on Medical Design Technology (<http://www.mdtmag.com>)

Tengion raises \$74M for organ programs

Mass Device

Tengion Inc. raises \$74.3 million to back its Neo-Kidney Augment and Neo-Urinary Conduit clinical programs.



[Tengion](#) [1] (NSDQ:[TNGN](#) [2]) said it raised \$74.3 million from 22 unnamed investors as it puts a pair of clinical programs through their paces.

The Winston-Salem, N.C.-based medical device company is developing the Neo-Kidney Augment and Neo-Urinary Conduit, human organs that are grown using a bioabsorbable scaffold and patients' own cells.

Last month Tengion shares soared after the company announced [a \\$33.6 million round](#) [3], including a \$15 million contribution from Celgene Corp. (NSDQ:[CELG](#) [4]) that came with the right of 1st refusal on Tengion's Neo-Kidney program.

Source URL (retrieved on 03/06/2015 - 9:18am):

<http://www.mdtmag.com/news/2013/08/tengion-raises-74m-organ-programs>

Links:

[1] <http://www.massdevice.com/company/tengion-inc>

[2] <http://www.google.com/finance?q=NASDAQ:TNGN>

[3] <http://www.massdevice.com/news/tengion-soars-raising-34m-support-organ-regeneration-platform>

[4] <https://www.google.com/finance?q=celgene&ei=jaECUtipLoSX0QGYnAE>